Kaya
Holdings, Inc. Psychedelics Subsidiary Taps Total Holistic Center™
to Develop Ketamine Treatment Model for Launch of Fifth Dimension
Therapeutics™ Mind Care Clinics
FT. LAUDERDALE, FL --
February 15, 2023 -- InvestorsHub NewsWire
-- Kaya
Holdings, Inc., ("KAYS" or the "Company") (OTCQB:
KAYS), a pioneer in the U.S. cannabis
industry, announced
today that its subsidiary Fifth Dimension Therapeutics™ (FDT) has
reached an agreement in principle with Florida-based Total Holistic
Center™ ("Total Holistic") to assist FDT with the development of
its ketamine treatment model as a first step in the launch of its
planned Fifth Dimension Therapeutics Mind Care Clinics and
Telehealth Services.
Dr. Anya
Temer of Total Holistic Center will be
developing
treatment protocols for KAYS'
Ketamine
Clinic and Telehealth Model to be Launched from
Holistic's
Boca
Raton, Lake Worth, and Miami Beach
Clinics
Initial
plans call for co-locating the Company's "Keta-Kaya" business
within Total Holistic Center's existing offices in Boca Raton, Fort
Worth and Miami Beach upon the completion of required protocols.
The hybrid Ketamine Clinic and Telehealth model will operate under
the direction of Dr. Anya Temer, who will initially serve as FDT's
Medical Director in Florida.
Off label
Ketamine Therapy has literally offered a new life to
some
afflicted
with treatment resistant depression (TRD) and PTSD, part of
a
Global
Suicide Epidemic that claims a life approximately every 40
seconds.
"This is our first step
in the rollout of our business plan that calls for us to establish
Fifth Dimension Therapeutics™ Mind Care Clinics and Telehealth
Operations in multiple geographic locations" stated W. David Jones,
a KAYS Senior Advisor and driving force behind the company's
developing psychedelic operations. "Ketamine, and soon psilocybin,
offer breakthrough opportunities to effectively confront
debilitating treatment resistant mental health conditions like
depression and PTSD. It is the potential to help people while
providing an exciting business opportunity motivates
us."
"I, and the entire
Holistic team, are excited to work with the Kaya team and implement
the Fifth Dimension Therapeutics ketamine therapy program. We look
forward to working with them in and potentially beyond Florida,"
said Dr. Anya Temer. "We are pleased to work together to innovate
psychedelic care delivery."
"We are working
diligently to develop the treatment experiences we believe will
most benefit our target customers. We believe that being able to
work with Dr. Temer and the Total Holistic Center team will
certainly contribute significantly to the high standards of
treatment to which we aspire" concluded KAYS' CEO Craig Frank. "As
our cannabis activities shift to more rapidly growing overseas
markets, we plan to focus more of our domestic U.S. efforts to
establishing Fifth Dimension Therapeutics™." The electricity in the
air has returned".
About
Ketamine Therapy
Ketamine was FDA approved
it as an anesthetic for people in 1970 and was used in treating
injured soldiers on the battlefields in the Vietnam War. Since that
time Emergency responders began to give it to an agitated patient
who, for example, they have rescued from a suicide attempt, which
has led Doctors to realize that the drug had powerful effects
against depression and suicidal thoughts.
Today, Ketamine has been
repurposed as an off-label analgesic and antidepressant. Extensive
investigation of its rapid anti-depressive effects has been a
breakthrough offering a potential lifesaving reprieve to those
suffering from Treatment Resistant Depression (TRD) and has also
been shown to reduce suicidal ideation in depressed patients at
risk for suicide. Similarly, the administration of ketamine was
effective at reducing depressive symptoms, acute suicidal behavior,
and mood lability in youth with TRD and bipolar disease.
In 2019, the Food and
Drug Administration (FDA) approved a nasal spray called esketamine,
derived from ketamine—an anesthetic that has made waves for its
surprising antidepressant effect. Intranasal esketamine is the only
form of ketamine that has been FDA-approved as a treatment for TRD.
However, Physicians have been prescribing racemic ketamine
off-label to patients with depression for at least two decades.
Additionally, Telehealth providers deliver oral tablets of ketamine
that are taken at home for convenience with remote monitoring
equipment and protocols for safety (also an off-label use). Using
an approved drug for unapproved purposes (such as Ozempic for
weight loss) is legal with the patient's informed
consent.
KAYS
SHAREHOLDERS AND OTHER INTERESTED PARTIES - PLEASE UPDATE YOUR
CONTACT INFORMATION
We routinely receive
calls and emails from shareholders asking us questions about KAYS,
so we are asking all KAYS shareholders to email us and confirm
their contact info. Please email info@kayaholdings.com with "KAYS
shareholder update" in the subject line and include your name,
address, phone number and number of shares you own so that we may
make sure you receive all updates and can respond to any
shareholder inquiries.
About
Dr. Anya Temer and Total Holistic Center (https://www.totalholisticcenter.com
)
Dr. Temer is the medical director and
chief practitioner at Total Holistic
Centers, a Florida based Alternative Healthcare Provider with
offices in Boca Raton, Fort Worth, and Miami
Beach.
Dr. Temer completed Bachelor degree
with a Major in Psychology from Hunter University. She received her
medical degree from the New York College of Osteopathic Medicine in
2011, completing her residency at Westchester General Hospital of
Florida in 2014. Since that time she has dedicated her career to
the holistic / integrative view of medicine that the human is not a
series of separate organs, but rather one cohesive unit that needs
to be viewed as a whole. Much of the therapy at Total Holistic
Center is focused on the mind - body connection while using the
latest personalized biometrics to understand the root cause of each
client's problems. Her
dedication to the "whole - person / root - cause"
approach sharpened during her residency as she saw imbalances
between such areas as patient treatment, nutrition, exercise, and
mental health.
About
Kaya Holdings, Inc. (www.kayaholdings.com
)
Kaya
Holdings, Inc. (OTCQB:KAYS)
is a Mind Care Company with longstanding operations as a
touch-the-plant, vertically integrated legal cannabis business
operating a number of majority-owned subsidiaries to retail,
cultivate, produce and distribute premium medical and recreational
cannabis products. The Company is evolving into a full mind care
enterprise with the planned introduction psilocybin at-home and
in-facility treatments, as permitted by law. KAYS is a fully
reporting, US-based publicly traded company, listed for trading on
the OTCQB Tier of the over-the-counter market under the symbol
KAYS.
Summary
of Operations
KAYS
corporate structure includes the following four majority-owned
subsidiaries, each responding to various demands and opportunities
in the cannabis or psychedelic industry:
Fifth
Dimension Therapeutics, Inc., serves as the
Company's operating branch to the psychedelic treatment sector,
including operation of mushroom cultivation facilities, in-facility
treatment centers, and at-home treatment programs.
Marijuana
Holdings Americas, Inc. owns the Kaya
Shack™ brand of licensed medical and recreational marijuana stores
(www.kayashack.com)
and the Kaya Farms™ brand of cannabis production and processing
operations that operate in the United States.
Kaya
Brands International, Inc., serves as the vehicle
for the Company's non-U.S. operations including cultivation
activities in Greece and Israel.
Kaya
Brands USA, Inc. owns a wide range of
proprietary brands of cannabis extracts, oils, pre-rolls, topicals,
edibles and beverages, cannaceuticals and related
accessories.
Important
Disclosure
KAYS is
planning execution of its stated business objectives in accordance
with current understanding of state and local laws and federal
enforcement policies and priorities as it relates to cannabis and
psychedelics. Potential investors and shareholders are cautioned
that KAYS and subsidiaries including FTD will obtain advice of
counsel prior to actualizing any portion of their business plan
(including but not limited to license applications for the
cultivation, distribution or sale of marijuana and psychedelic
products, engaging in said activities or acquiring existing
production/sales operations). Advice of counsel with regard to
specific activities of KAYS, federal, state or local legal action
or changes in federal government policy and/or state and local laws
may adversely affect business operations and shareholder
value.
Forward-Looking
Statements
This press
release includes statements that may constitute "forward-looking"
statements, usually containing the words "believe," "estimate,"
"project," "expect" or similar statements are made pursuant to the
safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. Forward-looking statements inherently involve risks
and uncertainties that could cause actual results to differ
materially from the forward-looking statements. Factors that would
cause or contribute to such differences include, but are not
limited to, acceptance of the Company's current and future products
and services in the marketplace, the ability of the Company to
develop effective new products and receive regulatory approvals of
such products, competitive factors, dependence upon third-party
vendors, and other risks detailed in the Company's periodic report
filings with the Securities and Exchange Commission. By making
these forward-looking statements, the Company undertakes no
obligation to update these statements for revisions or changes
after the date of this release.
For more
information contact Investor Relations: info@kayaholdings.com or
561-400-1971.
SOURCE: Kaya
Holdings, Inc.